Success Metrics

Clinical Success Rate

75.0%

Based on 3 completed trials

Completion Rate

75%(3/4)

Active Trials

0(0%)

Results Posted

33%(1 trials)

Terminated

1(20%)

Phase Distribution

Ph phase_1

20%

Ph phase_4

60%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

1(25.0%)

Phase 4Post-market surveillance

3(75.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Terminated(1)

Other(1)

Detailed Status

Completed3

Terminated1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

75.0%

Most Advanced

Phase 4

Trials by Phase

Phase 11 (25.0%)

Phase 43 (75.0%)

Trials by Status

terminated120%

unknown120%

completed360%

Recent Activity

0 active trials

Showing 5 of 5

completed

Real-Life Outcomes of TAF/FTC/BIC in HIV Patients in Colombia

NCT06829082

completedphase_4

Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program

NCT04650269

completedphase_1

The Effect of Biktarvy (B/F/TAF) on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers

NCT04950530

terminatedphase_4

Efficacy, Tolerability and Acceptability of Biktarvy by TPLWH

NCT04944654

unknownphase_4

Switch to TAF+FTC+BIC in HIV-1-infected Patients Over 65 Years Old at Risk of Polymedication

NCT04222283

Clinical Trials (5)

Showing 5 of 5 trials

NCT06829082

Real-Life Outcomes of TAF/FTC/BIC in HIV Patients in Colombia

Completed

NCT04650269Phase 4

Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program

Completed

NCT04950530Phase 1

The Effect of Biktarvy (B/F/TAF) on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers

Completed

NCT04944654Phase 4

Efficacy, Tolerability and Acceptability of Biktarvy by TPLWH

Terminated

NCT04222283Phase 4

Switch to TAF+FTC+BIC in HIV-1-infected Patients Over 65 Years Old at Risk of Polymedication

Unknown

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5